Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

272.05 -3.79 (-1.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Thursday's session: gap up and gap down stock in the S&P500 index
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
2 Unstoppable Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
What the Options Market Tells Us About Amgen
Via Benzinga
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance. 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Amgen
Via Benzinga
Amgen Unusual Options Activity For May 02
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
Is the Market Bullish or Bearish on Amgen?
Via Benzinga
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook and investor caution. 
Via Benzinga
Nasdaq 100 Leads Wall Street Rally As China Signals Openness To Fentanyl Talks, Easing Trade Tensions
U.S. stocks rose on hopes of China's willingness to negotiate a trade deal regarding fentanyl production. Tech stocks led the rally. 
Via Benzinga
Wall Street Eyes 9th Straight Day Of Gains, Apple Falls As Chinese Sales Disappoint: What's Driving Markets Friday?
U.S. stocks advanced across the board by midday Friday, with the S&P 500 eyeing its ninth consecutive day of gains—poised for the longest winning streak since May 2024. 
Via Benzinga
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities. 
Via MarketBeat
Topics Economy World Trade
Exposures COVID-19 Supply Chain Tariff
Amgen’s (NASDAQ:AMGN) Q1: Beats On Revenue
Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2025, with sales up 9.4% year on year to $8.15 billion. The company expects the full year’s revenue to be around $35... 
Via StockStory
Beat the Nasdaq With This Cash-Gushing Dividend Stock
Via The Motley Fool
Topics Economy Stocks
Exposures Economy US Equities
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday?
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully... 
Via Benzinga
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
Amgen (AMGN) Reports Earnings Tomorrow: What To Expect
Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Economy Tariff
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
The Week Ahead: PCE Inflation Data And Big Tech Earnings In Focus
Markets brace for crucial week with Big Tech earnings, Trump's 100-day milestone, and key economic data as trade concerns linger. 
Via Talk Markets
Topics Economy Government Stocks / Equities
Exposures Interest Rates Political
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Economy Intellectual Property World Trade
Exposures Economy Intellectual Property Tariff
1 Value Stock to Research Further and 2 to Ignore
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Exposures Political
Amgen, Franco-Nevada, Take-Two Interactive And More: CNBC's 'Final Trades'
Via Benzinga
Short Week Finishes With Netflix Q1 Beat
Considering the blue-chip Dow face-planted ahead of the open on a disappointing Q1 report from UnitedHealth, which resulted in a -22% tanking by Thursday’s close, this was a pretty flat day. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035. 
Via Benzinga
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market. 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Sandoz Files Antitrust Lawsuit Against Amgen Over Inflammation Drug, Seeks Damages: Retail Sentiment Falters
Sandoz is seeking an injunction to prevent Amgen from using patent rights to block biosimilar competition and allow Sandoz to launch its Erelzi “as soon as possible.” 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.